SunTrust Defends Biogen (BIIB); 'Buy on Weakness'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Biogen (BIIB) 6% Lower as Aducanumab Timeline Pushed Out
April 22, 2020 7:50 AM EDTBiogen (NASDAQ: BIIB) is down 6% in pre-open trading despite strong results as the company said it stated submitting modules for aducanumab BLA and expects the U.S. filing in the third quarter, which pushes out the launch timelines.
... MoreBiogen (BIIB) Tops Q1 EPS by $1.40
April 22, 2020 7:04 AM EDTBiogen (NASDAQ: BIIB) reported Q1 EPS of $9.14, $1.40 better than the analyst estimate of $7.74. Revenue for the quarter came in at $3.53 billion versus the consensus estimate of $3.41 billion.
For earnings history and earnings-related data on Biogen (BIIB) click here.
... More